Tumor Fraction-based Prognostic Tool for Cancer Patients Referred to Early Phase Clinical Trials

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2024 Oct 7

PMID 39375508

Authors

Arnaud Bayle

Laila Belcaid

Sophie Cousin

Kilian Trin

Melissa Alame

Etienne Rouleau

Isabelle Soubeyran

Ludovic Lacroix

Laura Blouin

Damien Vasseur

Amandine Crombe

Simone Mathoulin-Pelissier

Jean-Charles Soria

Carine Bellera

Antoine Italiano

Affiliations

Soon will be listed here.

Abstract

Selecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.

References

Reichert Z, Morgan T, Li G, Castellanos E, Snow T, DallOlio F . Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol. 2022; 34(1):111-120. PMC: 9805517. DOI: 10.1016/j.annonc.2022.09.163. View

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S . Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017; 84:212-218. DOI: 10.1016/j.ejca.2017.07.027. View

Chihara D, Lin R, Flowers C, Finnigan S, Cordes L, Fukuda Y . Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022; 400(10351):512-521. PMC: 9477645. DOI: 10.1016/S0140-6736(22)01390-3. View

Rolfo C, Mack P, Scagliotti G, Aggarwal C, Arcila M, Barlesi F . Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021; 16(10):1647-1662. DOI: 10.1016/j.jtho.2021.06.017. View

Chau N, Florescu A, Chan K, Wang L, Chen E, Bedard P . Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?. BMC Cancer. 2011; 11:426. PMC: 3199018. DOI: 10.1186/1471-2407-11-426. View

Pessoa L, Heringer M, Ferrer V . ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020; 155:103109. DOI: 10.1016/j.critrevonc.2020.103109. View

Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C . Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine. 2020; 54:102728. PMC: 7186589. DOI: 10.1016/j.ebiom.2020.102728. View

Chakiba C, Grellety T, Bellera C, Italiano A . Encouraging Trends in Modern Phase 1 Oncology Trials. N Engl J Med. 2018; 378(23):2242-2243. DOI: 10.1056/NEJMc1803837. View

Arkenau H, Olmos D, Ang J, de Bono J, Judson I, Kaye S . Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer. 2008; 98(6):1029-33. PMC: 2275488. DOI: 10.1038/sj.bjc.6604218. View

10.

Keller L, Belloum Y, Wikman H, Pantel K . Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2020; 124(2):345-358. PMC: 7852556. DOI: 10.1038/s41416-020-01047-5. View

11.

Pascual J, Attard G, Bidard F, Curigliano G, De Mattos-Arruda L, Diehn M . ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022; 33(8):750-768. DOI: 10.1016/j.annonc.2022.05.520. View

12.

Italiano A . Participation in phase 1 trials for patients with cancer. Lancet. 2022; 400(10351):473-475. DOI: 10.1016/S0140-6736(22)01533-1. View

13.

Schutte K, Brulport F, Harguem-Zayani S, Schiratti J, Ghermi R, Jehanno P . An artificial intelligence model predicts the survival of solid tumour patients from imaging and clinical data. Eur J Cancer. 2022; 174:90-98. DOI: 10.1016/j.ejca.2022.06.055. View

14.

Arkenau H, Olmos D, Ang J, Barriuso J, Karavasilis V, Ashley S . 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?. Eur J Cancer. 2008; 44(11):1536-40. DOI: 10.1016/j.ejca.2008.04.017. View

15.

Choudhury A, Werner L, Francini E, Wei X, Ha G, Freeman S . Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. 2018; 3(21). PMC: 6238737. DOI: 10.1172/jci.insight.122109. View

16.

Stover D, Parsons H, Ha G, Freeman S, Barry W, Guo H . Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018; 36(6):543-553. PMC: 5815405. DOI: 10.1200/JCO.2017.76.0033. View